Greenwich LifeSciences wins FDA Fast Track status (GLSI)

Group 1 - Greenwich LifeSciences (NASDAQ:GLSI) experienced a ~32% increase in premarket trading following the U.S. FDA's Fast Track designation for its lead asset GLSI-100, aimed at treating a specific subset of breast cancer patients [4] - The Fast Track status granted by the FDA is significant as it facilitates the development and expedites the review of drugs intended to treat serious conditions and fill an unmet medical need [4] - GLSI-100 is positioned to potentially improve treatment options for breast cancer patients, indicating a positive outlook for the company's future performance in the oncology sector [4]